The company
Bolt Biotherapeutics, Inc.
BOLT · Nasdaq
BOLT stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 5.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Setting up
- Weeks in an uptrend
- out for 36
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $11K
- Insider sales, 12 months
- $257K
- Officials’ trades on record
- 0
- Institutions holding
- 24 (+1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| William P. QuinnPresident, CEO and CFO | sold | 9,132at $3.24 | 18 Sep 2026filed 21 Sep 2026 |
| Sarah NemecSenior VP, Finance and PAO | sold | 4,077at $3.24 | 18 Sep 2026filed 21 Sep 2026 |
| Grant YonehiroChief Operating Officer | sold | 6,850at $3.24 | 18 Sep 2026filed 21 Sep 2026 |
| William P. QuinnPresident, CEO and CFO | sold | 6,545at $3.32 | 17 Sep 2026filed 21 Sep 2026 |
| Sarah NemecSenior VP, Finance and PAO | sold | 2,922at $3.32 | 17 Sep 2026filed 21 Sep 2026 |
| Grant YonehiroChief Operating Officer | sold | 4,909at $3.32 | 17 Sep 2026filed 21 Sep 2026 |
| William P. QuinnPresident, CEO and CFO | sold | 1,889at $3.77 | 16 Sep 2026filed 21 Sep 2026 |
| Sarah NemecSenior VP, Finance and PAO | sold | 843at $3.77 | 16 Sep 2026filed 21 Sep 2026 |
| Grant YonehiroChief Operating Officer | sold | 1,417at $3.77 | 16 Sep 2026filed 21 Sep 2026 |
| William P. QuinnPresident, CEO and CFO | bought | 637at $3.88 | 5 Jun 2026filed 21 Sep 2026 |
| Sarah NemecSenior VP, Finance and PAO | bought | 509at $3.88 | 5 Jun 2026filed 21 Sep 2026 |
| Sarah NemecSenior VP, Finance and PAO | bought | 125at $4.61 | 5 Dec 2025filed 4 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Sofinnova Investments, Inc.unchanged · filed 14 Aug 2026 | 137,721$530K | 00.0% |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 98,625$380K | +21,400+27.7% |
| Vivo Capital, LLCunchanged · filed 14 Aug 2026 | 72,414$279K | 00.0% |
| CITADEL ADVISORS LLCadded · filed 14 Aug 2026 | 56,903$219K | +46,794+462.9% |
| T3 Companies, LLCunchanged · filed 27 Jul 2026 | 38,000$146K | 00.0% |
| Board of Trustees of The Leland Stanford Junior Universityunchanged · filed 12 Aug 2026 | 35,977$139K | 00.0% |
| Pfizer Incunchanged · filed 13 Aug 2026 | 31,305$134K | 00.0% |
| Lynx1 Capital Management LPunchanged · filed 12 Aug 2026 | 30,800$119K | 00.0% |
| NANO CAP NEW MILLENNIUM GROWTH FUND L Punchanged · filed 14 Aug 2026 | 27,500$106K | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 19,119$74K | -9,672−33.6% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.